Related Experiment Video
Updated: Aug 24, 2026

An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function
Published on: May 4, 2021
Rottlerin inhibits multiple steps involved in insulin-induced glucose uptake in 3T3-L1 adipocytes
Merlijn Bazuine1, Gerard C M van der Zon, Rob van de Ven
1Department of Molecular Cell Biology, Leiden University Medical Center, Wassenaarseweg 72, P.O. Box 9503, 2333 AL Leiden, The Netherlands.
Abstract:
Recently, it was shown that rottlerin inhibits insulin-stimulated glucose uptake and reduces intracellular adenosine triphosphate (ATP) levels in 3T3-L1 adipocytes, suggesting that these two events are causally linked. However, several other reports show that ATP-depletion induces glucose uptake in both muscle cells and adipocytes. In the present study, the mechanism of inhibition by rottlerin was studied in detail, in order to resolve this apparent discrepancy. It was found that rottlerin strongly reduces insulin-stimulated 2-deoxyglucose (2-DOG) uptake in 3T3-L1 adipocytes by a partial inhibition of the translocation of the insulin-responsive GLUT4 glucose transporter towards the plasma membrane (PM). Whereas the insulin-induced phosphatidyl-inositol-3' (PI-3') kinase signaling pathway is unaffected by rottlerin, Cbl tyrosine phosphorylation, which provides an essential, PI-3' kinase-independent signal towards GLUT4 translocation, is markedly attenuated. Furthermore, we also observed a direct inhibitory effect of rottlerin on insulin-induced glucose uptake in 3T3-L1 adipocytes. The direct inhibition of insulin-stimulated 2-DOG uptake by rottlerin displayed characteristics of uncompetitive inhibition: with the K(m(app)) of glucose uptake reduced from 1.6 to 0.9 mM and the V(max(app)) reduced from 5.2 to 1.0 nmol/minmg in the presence of rottlerin. In conclusion, rottlerin inhibits multiple steps involved in insulin-stimulated 2-DOG uptake in 3T3-L1 adipocytes. The observed reduction in GLUT4 translocation towards the PM and the uncompetitive inhibition of the glucose transport process provide alternative explanations for the inhibitory effects of rottlerin aside from the effects of rottlerin on intracellular levels of ATP.
Insights
Rottlerin inhibits insulin-stimulated glucose uptake in adipocytes by reducing GLUT4 transporter movement and directly interfering with glucose transport. This provides new explanations beyond ATP level changes.
Area of Science:
- Cell biology
- Biochemistry
- Metabolism
Background:
- Rottlerin's effect on glucose uptake and ATP levels in 3T3-L1 adipocytes is debated.
- Conflicting reports exist regarding ATP depletion's impact on glucose uptake in muscle and fat cells.
Purpose of the Study:
- To elucidate the precise mechanism by which rottlerin inhibits insulin-stimulated glucose uptake.
- To resolve discrepancies concerning rottlerin's effects on ATP levels and glucose transport.
Main Methods:
- Investigated rottlerin's impact on 2-deoxyglucose (2-DOG) uptake in 3T3-L1 adipocytes.
- Analyzed the translocation of the GLUT4 glucose transporter to the plasma membrane.
- Examined the effects on the phosphatidyl-inositol-3' (PI-3') kinase pathway and Cbl tyrosine phosphorylation.
- Performed kinetic analysis of rottlerin's inhibition of glucose uptake.
Main Results:
- Rottlerin partially inhibited GLUT4 translocation to the plasma membrane.
- The PI-3' kinase pathway remained unaffected, but Cbl tyrosine phosphorylation was attenuated.
- Rottlerin exhibited uncompetitive inhibition of glucose uptake, reducing both K(m(app)) and V(max(app)).
Conclusions:
- Rottlerin inhibits insulin-stimulated 2-deoxyglucose uptake through multiple mechanisms.
- Reduced GLUT4 translocation and uncompetitive inhibition of transport are key effects.
- These findings offer alternative explanations for rottlerin's inhibitory action, independent of ATP level alterations.
Related Concept Videos
Insulin: The Receptor and Signaling Pathways
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
PI3K/mTOR/AKT Signaling Pathway
Dipeptidyl Peptidase 4 Inhibitors
Insulin Secretory Vesicles
